Surging ahead in the RSV race, Pfizer buys out a PhII player in $525M M&A pact - Endpoints News

Right on the heels of back-to-back breakthrough therapy designations for its lead RSV vaccine, Pfizer is wagering up to $525 million on a biotech buyout that injects new RSV assets into its pipeline. Pfizer is snapping up ReViral after inspecting mid-stage da…

Three months after initiating layoffs, hitting pause on a planned COPD study and terminating an agreement with the COPD Foundation, Kaleido Biosciences is now shutting down. On Friday, the biotech’s… [+439 chars]

full article...